Discontinued — last reported Q1 '23
Products & Services · Income (loss) from equity method investments
ADUHELM — Income (loss) from equity method investments
Year-over-year, this metric grew by 130.5%, from $59.00M to $136.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2021
Last reportedQ1 2023
Rolls up toEquity Method Income
How to read this metric
An increase indicates successful performance of the partner entity, while a decrease signals underperformance or losses in the joint venture.
Detailed definition
This represents the company's share of profits or losses from entities where it holds significant influence but not full...
Peer comparison
Standard for companies utilizing joint ventures to share development and commercialization risks.
Metric ID:
biib_segment_aduhelm_income_loss_from_equity_method_investmentsHistorical Data
8 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | |
|---|---|---|---|---|---|---|---|---|
| Value | $45.00M | $45.00M | $45.00M | $59.00M | $45.00M | $41.00M | $0.00 | $136.00M |
| QoQ Change | — | +0.0% | +0.0% | +31.1% | -23.7% | -8.9% | -100.0% | — |
| YoY Change | — | — | — | — | +0.0% | -8.9% | -100.0% | +130.5% |
Range$0.00 – $136.00M
CAGR+88.1%
Avg YoY Growth+5.4%
Median YoY Growth-4.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aduhelm — income (loss) from equity method investments?
- Biogen (BIIB) reported aduhelm — income (loss) from equity method investments of $136.00M in Q1 2023.
- How has Biogen's aduhelm — income (loss) from equity method investments changed year-over-year?
- Biogen's aduhelm — income (loss) from equity method investments increased by 130.5% year-over-year, from $59.00M to $136.00M.
- What does aduhelm — income (loss) from equity method investments mean?
- The company's portion of earnings or losses from its strategic partnerships.